Latest news with #BainCapital-backed
Time of India
a day ago
- Business
- Time of India
Bain Capital-backed Heartflow valued at $2.27 billion in solid Nasdaq debut
New York: Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares surging 47.4% in the Nasdaq debut , as the IPO market gathers momentum and outrides tariff worries. The shares opened at $28 and went as high as $31.5, signaling robust investor appetite for companies leveraging artificial intelligence for healthcare. Heartflow sold about 16.67 million shares at $19 each in its IPO on Thursday, raising $316.7 million. The Bain Capital-backed company's debut comes as expectations of a softer trade policy and lower interest rates boost investor sentiment , which had nosedived after U.S. tariffs in April stoked recession fears. The market sentiment reflects "nervous excitement", said Matt Kennedy, senior strategist at IPO-focused research and ETFs provider Renaissance Capital. "We saw a spike in volatility last week, but at the same time stocks (are) flying up on AI-driven earnings blowouts." Space tech startup Firefly Aerospace and design software firm Figma saw stellar first-day reactions in recent days, strengthening prospects for tech-focused companies to go public. Heartflow's first-day pop could help boost market perception for other medtechs, which often rely on vast research and development expenditure, with clinical testing further pressuring the bottom line. Beta Bionics and Kestra Medical had solid debuts earlier this year, but are now trading below their IPO price, like most medtech IPOs of the past year. "If investors keep losing, they just won't show up and companies will struggle to raise IPO funding," Kennedy added, referring to underwhelming post-listing performance from several medtech IPOs in the past year. Founded in 2007, Heartflow helps physicians diagnose and treat heart disease. Its AI-enabled products can create a personalized 3D model of a patient's heart via a single specialized scan. The company's revenue rose 39% in the quarter ended March 31 from a year ago. Its losses, however, widened 55% to $32.35 million during the same period.
Time of India
2 days ago
- Business
- Time of India
Bain Capital-backed Heartflow valued at $2.27 billion in solid Nasdaq debut
Academy Empower your mind, elevate your skills Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares surging 47.4% in the Nasdaq debut , as the IPO market gathers momentum and outrides tariff shares opened at $28 and went as high as $31.5, signaling robust investor appetite for companies leveraging artificial intelligence for sold about 16.67 million shares at $19 each in its IPO on Thursday, raising $316.7 Bain Capital-backed company's debut comes as expectations of a softer trade policy and lower interest rates boost investor sentiment , which had nosedived after U.S. tariffs in April stoked recession market sentiment reflects "nervous excitement", said Matt Kennedy, senior strategist at IPO-focused research and ETFs provider Renaissance Capital."We saw a spike in volatility last week, but at the same time stocks (are) flying up on AI-driven earnings blowouts."Space tech startup Firefly Aerospace and design software firm Figma saw stellar first-day reactions in recent days, strengthening prospects for tech-focused companies to go first-day pop could help boost market perception for other medtechs, which often rely on vast research and development expenditure, with clinical testing further pressuring the bottom Bionics and Kestra Medical had solid debuts earlier this year, but are now trading below their IPO price, like most medtech IPOs of the past year."If investors keep losing, they just won't show up and companies will struggle to raise IPO funding," Kennedy added, referring to underwhelming post-listing performance from several medtech IPOs in the past in 2007, Heartflow helps physicians diagnose and treat heart AI-enabled products can create a personalized 3D model of a patient's heart via a single specialized company's revenue rose 39% in the quarter ended March 31 from a year ago. Its losses, however, widened 55% to $32.35 million during the same period.
Yahoo
3 days ago
- Business
- Yahoo
Bain Capital-backed Heartflow valued at $2.27 billion in solid Nasdaq debut
By Rishab Shaju and Ateev Bhandari (Reuters) -Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares surging 47.4% in the Nasdaq debut, as the IPO market gathers momentum and outrides tariff worries. The shares opened at $28 and went as high as $31.5, signaling robust investor appetite for companies leveraging artificial intelligence for healthcare. Heartflow sold about 16.67 million shares at $19 each in its IPO on Thursday, raising $316.7 million. The Bain Capital-backed company's debut comes as expectations of a softer trade policy and lower interest rates boost investor sentiment, which had nosedived after U.S. tariffs in April stoked recession fears. The market sentiment reflects "nervous excitement", said Matt Kennedy, senior strategist at IPO-focused research and ETFs provider Renaissance Capital. "We saw a spike in volatility last week, but at the same time stocks (are) flying up on AI-driven earnings blowouts." Space tech startup Firefly Aerospace and design software firm Figma saw stellar first-day reactions in recent days, strengthening prospects for tech-focused companies to go public. Heartflow's first-day pop could help boost market perception for other medtechs, which often rely on vast research and development expenditure, with clinical testing further pressuring the bottom line. Beta Bionics and Kestra Medical had solid debuts earlier this year, but are now trading below their IPO price, like most medtech IPOs of the past year. "If investors keep losing, they just won't show up and companies will struggle to raise IPO funding," Kennedy added, referring to underwhelming post-listing performance from several medtech IPOs in the past year. Founded in 2007, Heartflow helps physicians diagnose and treat heart disease. Its AI-enabled products can create a personalized 3D model of a patient's heart via a single specialized scan. The company's revenue rose 39% in the quarter ended March 31 from a year ago. Its losses, however, widened 55% to $32.35 million during the same period.
Malaysian Reserve
04-07-2025
- Business
- Malaysian Reserve
Bridge Data Centres Unveils Inaugural ESG Report, Outlines Vision for a Sustainable Digital Future
Significant advances in innovative cooling technologies in past year lowered power usage effectiveness (PUE) in subtropical regions to below 1.2 Report details six environmental performance domains — water resources management, high-efficiency thermal management, energy system resilience, carbon footprint reduction, green technology R&D, and digital energy governance SINGAPORE, July 4, 2025 /PRNewswire/ — Bridge Data Centres, a Bain Capital-backed hyperscale data centre platform, has unveiled its inaugural environmental, social and governance (ESG) report, detailing its blueprint for a sustainable data centre future. The rapid growth of data centre development across the Asia-Pacific region has intensified demand for high-performance, secure, and globally accessible computing. As data volumes surge and complexity increases, expectations are rising — data centres must deliver greater efficiency and reliability while reducing their environmental impact. Bridge Data Centres (BDC) is addressing these evolving demands through sustainability-led innovation. The ESG report details how the company is investing in energy-efficient systems, accelerating its transition to renewable energy, enhancing supply chain performance, and committing to emissions reductions. Ahead of the report's release, BDC established a three-tier ESG governance framework comprising governance, management, and execution layers, with the Board of Directors providing top-level oversight. Eric Fan, Chairman of Bridge Data Centres ESG Committee, commented, 'This inaugural ESG report is a testament to our commitment to building a future that is sustainable, equitable, and resilient. It reflects our core belief that the long-term success of our company is inseparable from the health of our planet, the well-being of our communities, and the trust we earn from our stakeholders.' The report highlights several technological milestones across six environmental performance domains — water resources management, high-efficiency thermal management, energy system resilience, carbon foot print reduction, green technology R&D, and digital energy governance. Backed by 588 patents, BDC has made significant strides in water recycling and on-site treatment systems to improve Water Usage Effectiveness (WUE). Breakthroughs in cooling technologies have lowered Power Usage Effectiveness (PUE) in subtropical regions to below 1.2 — setting a new company milestone for energy efficiency. In Thailand, BDC's facility generated 511 MWh of renewable energy through rooftop solar panels. Additionally, innovations in construction technology have enabled a 30% reduction in construction cycles, accelerating customer deployment while reducing construction-related waste. Bridge Data Centres is now a member of RE100 and has committed to achieving 100% renewable energy usage by 2040. BDC has also submitted goals to Science-based Targets Initiative (SBTi). The ESG report also details BDC's social impact. Over the past year, BDC has increased employment by over 24% year-on-year, with 85% of new hires hired in local markets, generating localized job opportunities and contributing to talent development for the data centre sector. Women represented 33.3% of the BDC executive management team – a notable figure in the data centre industry. 'As a digital infrastructure designer and builder, we have a unique responsibility — and powerful opportunity — to lead the way in sustainability. The choices we make today in design, construction, and operations will shape the future of our environment and society,' added Mr Fan. Download the Bridge Data Centres inaugural ESG report here: About Bridge Data Centres Backed by global leading investment firm Bain Capital, Bridge Data Centres is a pan-Asian hyperscale data infrastructure builder, striving for an ever-growing and transforming digital future. We focus on empowering our clients and their cloud-first and AI-driven strategy, through our hyperscale, build-to-suit, and colocation data solutions.
&w=3840&q=100)
Business Standard
04-07-2025
- Business
- Business Standard
Emcure Pharma shares dip after 2.4% stake change hands in block trades
Shares of Emcure Pharmaceuticals fell over 2 per cent on Friday after about 4.53 million shares changed hands in block trades during market opening. The pharmaceutical company's stock fell as much as 2.33 per cent during the day to ₹1,250 per share, the biggest intraday fall since June 26 this year. The stock pared losses to trade 1.9 per cent lower at ₹1,255 apiece, compared to a 0.2 per cent decline in Nifty 50 as of 12:22 PM. Shares of the company have fallen 10 per cent from its recent highs of ₹1,403 apiece, which it hit in May. The stock currently trades at 41 times the average 30-day trading volume, according to Bloomberg. The counter has fallen 13.5 per cent this year, compared to a 7.5 per cent advance in the benchmark Nifty 50. Emcure Pharmaceuticals has a total market capitalisation of ₹23,862.89 crore. Emcure Pharma block trade The company's shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the National Stock Exchange, according to Bloomberg data. Buyers and sellers were not known immediately. However, reports said that Bain Capital-backed BC Investments IV was looking to offload a 2.4 per cent stake in the pharma major for ₹551 crore. The floor price for the transaction was set at ₹1,279.80 per share, the reports added. As of BSE shareholding data, BC Investments IV had an 8.68 per cent stake in Emcure Pharmaceuticals as of the March 2025 quarter. Emcure Pharma Q4 results Emcure Pharmaceuticals posted a 63 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at ₹197.2 crore for the March quarter of the financial year 2024–25 (Q4FY25), up from ₹121 crore in the same period last year. The company's revenue from operations rose to ₹2,116.2 crore, a 19.5 per cent increase from ₹1,771.3 crore in Q4FY24. Emcure's domestic business grew by 24.8 per cent Y-o-Y to ₹929 crore, led by growth in its women's health and cardiology franchises. 'It was further aided by our new focus areas of dermatology and over-the-counter (OTC),' the company said in a regulatory filing to the exchanges. About Emcure Pharmaceuticals Emcure Pharma has over 350 brands, five research and development (R&D) centres, and 13 manufacturing facilities established across the country. Outside India, it has a wide network across 70 countries. The company's API facilities ensure that the supply chain is vertically integrated, providing flexibility over control of manufacturing.
